Literature DB >> 9920660

Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.

M Kim1, H S Lee, G LaForet, C McIntyre, E J Martin, P Chang, T W Kim, M Williams, P H Reddy, D Tagle, F M Boyce, L Won, A Heller, N Aronin, M DiFiglia.   

Abstract

Neuronal intranuclear inclusions are found in the brains of patients with Huntington's disease and form from the polyglutamine-expanded N-terminal region of mutant huntingtin. To explore the properties of inclusions and their involvement in cell death, mouse clonal striatal cells were transiently transfected with truncated and full-length human wild-type and mutant huntingtin cDNAs. Both normal and mutant proteins localized in the cytoplasm, and infrequently, in dispersed and perinuclear vacuoles. Only mutant huntingtin formed nuclear and cytoplasmic inclusions, which increased with polyglutamine expansion and with time after transfection. Nuclear inclusions contained primarily cleaved N-terminal products, whereas cytoplasmic inclusions contained cleaved and larger intact proteins. Cells with wild-type or mutant protein had distinct apoptotic features (membrane blebbing, shrinkage, cellular fragmentation), but those with mutant huntingtin generated the most cell fragments (apoptotic bodies). The caspase inhibitor Z-VAD-FMK significantly increased cell survival but did not diminish nuclear and cytoplasmic inclusions. In contrast, Z-DEVD-FMK significantly reduced nuclear and cytoplasmic inclusions but did not increase survival. A series of N-terminal products was formed from truncated normal and mutant proteins and from full-length mutant huntingtin but not from full-length wild-type huntingtin. One prominent N-terminal product was blocked by Z-VAD-FMK. In summary, the formation of inclusions in clonal striatal cells corresponds to that seen in the HD brain and is separable from events that regulate cell death. N-terminal cleavage may be linked to mutant huntingtin's role in cell death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920660      PMCID: PMC6782141     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  31 in total

1.  Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract.

Authors:  Y P Goldberg; D W Nicholson; D M Rasper; M A Kalchman; H B Koide; R K Graham; M Bromm; P Kazemi-Esfarjani; N A Thornberry; J P Vaillancourt; M R Hayden
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

2.  Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?

Authors:  A J Cooper; K F Sheu; J R Burke; O Onodera; W J Strittmatter; A D Roses; J P Blass
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

3.  A DEVD-inhibited caspase other than CPP32 is involved in the commitment of cerebellar granule neurons to apoptosis induced by K+ deprivation.

Authors:  S R D'Mello; F Aglieco; M R Roberts; K Borodezt; J W Haycock
Journal:  J Neurochem       Date:  1998-05       Impact factor: 5.372

4.  Huntingtin localization in brains of normal and Huntington's disease patients.

Authors:  E Sapp; C Schwarz; K Chase; P G Bhide; A B Young; J Penney; J P Vonsattel; N Aronin; M DiFiglia
Journal:  Ann Neurol       Date:  1997-10       Impact factor: 10.422

5.  Expression of normal and mutant huntingtin in the developing brain.

Authors:  P G Bhide; M Day; E Sapp; C Schwarz; A Sheth; J Kim; A B Young; J Penney; J Golden; N Aronin; M DiFiglia
Journal:  J Neurosci       Date:  1996-09-01       Impact factor: 6.167

6.  Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

Authors:  S W Davies; M Turmaine; B A Cozens; M DiFiglia; A H Sharp; C A Ross; E Scherzinger; E E Wanker; L Mangiarini; G P Bates
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

7.  Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways.

Authors:  J Velier; M Kim; C Schwarz; T W Kim; E Sapp; K Chase; N Aronin; M DiFiglia
Journal:  Exp Neurol       Date:  1998-07       Impact factor: 5.330

8.  Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

Authors:  F Saudou; S Finkbeiner; D Devys; M E Greenberg
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

9.  Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.

Authors:  P Kahlem; H Green; P Djian
Journal:  Mol Cell       Date:  1998-03       Impact factor: 17.970

10.  Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.

Authors:  M W Becher; J A Kotzuk; A H Sharp; S W Davies; G P Bates; D L Price; C A Ross
Journal:  Neurobiol Dis       Date:  1998-04       Impact factor: 5.996

View more
  66 in total

1.  Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.

Authors:  E Martín-Aparicio; A Yamamoto; F Hernández; R Hen; J Avila; J J Lucas
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 2.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 3.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 4.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 5.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

6.  Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor.

Authors:  M I Diamond; M R Robinson; K R Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

7.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

Review 8.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

9.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

Authors:  Elizabeth J Slow; Rona K Graham; Alexander P Osmand; Rebecca S Devon; Ge Lu; Yu Deng; Jacqui Pearson; Kuljeet Vaid; Nagat Bissada; Ronald Wetzel; Blair R Leavitt; Michael R Hayden
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

10.  Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.

Authors:  Liliana B Menalled; Jessica D Sison; Ying Wu; Melisa Olivieri; Xiao-Jiang Li; He Li; Scott Zeitlin; Marie-Françoise Chesselet
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.